Doxorubicin is a chemotherapeutic agent that is commonly used to treat a broad range of
cancers. However, significant cardiotoxicity, associated with prolonged exposure to doxorubicin…

Background Doxorubicin is one of the most effective anti-cancer drugs but its use is limited
by cumulative cardiotoxicity that restricts lifetime dose. Redox damage is one of the most …

The immature phenotype of stem cell derived cardiomyocytes is a significant barrier to their
use in translational medicine and pre-clinical in vitro drug toxicity and pharmacological …

Enhancing the early detection of new therapies that are likely to carry a safety liability in the
context of the intended patient population would provide a major advance in drug discovery. …

Functional changes to cardiomyocytes are a common cause of attrition in preclinical and
clinical drug development. Current approaches to assess cardiomyocyte contractility in vitro are …

Pharmaceutical agents despite their efficacy to treat disease can cause additional unwanted
cardiovascular side effects. Cardiotoxicity is characterized by changes in either the function …

Functional human-on-a-chip systems hold great promise to enable quantitative translation
to in vivo outcomes. Here, we explored this concept using a pumpless heart only and heart:…

Defining an appropriate and efficient assessment of drug‐induced corrected QT interval (QTc)
prolongation (a surrogate marker of torsades de pointes arrhythmia) remains a concern of …

Untargeted metabolomics is an established approach in toxicology for characterising
endogenous metabolic responses to xenobiotic exposure. Detecting the xenobiotic and its …

Cardiotoxicity is a common cause of attrition in preclinical and clinical drug development.
Current in vitro approaches have two main limitations, they either are limited to low throughput …